BioSeek to Collaborate with Merck Serono to Assess Potential Drug Candidates
News May 27, 2008
Under the collaboration, BioSeek will apply its BioMAP® Systems to evaluate Merck Serono small molecule compounds and proteins across multiple therapeutic areas in support of target differentiation, lead selection, and nomination of candidates for preclinical development at Merck Serono. Financial details were not disclosed.
“We are delighted that Merck Serono has chosen BioSeek as a partner to explore the utility of predictive human biology for the enhancement and acceleration of modern drug discovery,” commented Michael C. Venuti, Ph.D., Chief Executive Officer of BioSeek.
“BioMAP Systems should provide an important value-added tool for the evaluation of compounds in Merck Serono’s autoimmune and inflammatory disease programs, with additional applications in neurodegenerative diseases and oncology.”
BioMAP® Systems are primary cell-based models of human disease biology, designed to replicate the intricate cell and pathway interactions as they are observed in vascular inflammation, cardiovascular and respiratory diseases, fibrosis and related clinical indications.
Depending on their mechanism of action, compounds induce specific patterns of changes in these systems (BioMAP profiles) that can be compared to a large number of reference profiles in the BioMAP Database. Assessment with BioMAP provides early insight into human pharmacological properties of compounds, including on- and off-target effects, dose responses, and the discrimination of closely related compounds.
Scientists from the UNC School of Medicine discovered that the anti-inflammatory protein NLRP12 normally helps protect mice against obesity and insulin resistance when they are fed a high-fat diet. The researchers also reported that the NLRP12 gene is underactive in people who are obese, making it a potential therapeutic target for treating obesity and diabetes.READ MORE
Nonalcoholic fatty liver disease produces no noticeable symptoms, but one out of every five people with it will go on to develop a more serious conditions such as nonalcoholic steatohepatosis and cirrhosis. Three new studies investigate how mitochondrial energy production is altered by the progress of fatty liver disease.READ MORE